NCT07097727View on ClinicalTrials.gov

Evaluation of the Role of Acetyl Cysteine in Ventilator Associated Pneumonia by Carbapenem Resistance Klebsiella

PHASE1CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

October 30, 2023

Primary Completion Date

September 30, 2024

Study Completion Date

October 30, 2024

Conditions
Ventilator Associated Pneumonia ( VAP)Mechanical Ventilation
Interventions
DRUG

acetyl cysteine 600 mg

patients received acetyl cysteine 600 mg/ 12h IV in addition to antibiotics

DRUG

antibiotics and saline.

patients received only antibiotics and saline

Trial Locations (1)

Unknown

Tanta University, Tanta

All Listed Sponsors
lead

Tanta University

OTHER

NCT07097727 - Evaluation of the Role of Acetyl Cysteine in Ventilator Associated Pneumonia by Carbapenem Resistance Klebsiella | Biotech Hunter | Biotech Hunter